Publicerad: 2021-02-16 14:24 | Uppdaterad: 2021-02-16 14:29

Aktuella utlysningar, vecka 7, 2021

Grants Office tipsar om aktuella utlysningar.

Svenska och nordiska utlysningar

Forskningsstipendium – AstraZeneca och Svenska Kardiologföreningen

Stöder klinisk forskning inom området hjärtsvikt. Stipendiet är värt SEK 100,000.

Closing date: 28 February 2021

Further information

Research Grant - Aroseniusfonden

Supports scientific research on hemophilia, von Willebrand's disease, immunological thrombocytopenic purpura and other closely related diseases. The grant is worth SEK 200,000.

Closing date: 8 March 2021

Further information

Swedish Research Council

Research project grant within medicine and health

Grant for half-time research position in a clinical environment

Research project grant for development of methods to replace, reduce and refine animal experiments

Starting grant within medicine and health

Research environment grant for interdisciplinary research

Project grant for research on viruses and virus-caused disease conditions

Grant for half-time research within healthcare sciences

Closing date: 17 March 2021

Swedish Cancer Society

Research projects

These grants support research projects in all forms of cancer research. Funding is worth up to SEK 2.5 million per year for up to three years.

Bidrag för planeringsgrupper

Syftar till att sammanföra forskargrupper och forskare med likartad metodologisk eller ämnesmässig tillhörighet, för att öka samarbete och informationsutbyte och att underlätta planering av flercenterstudier. Bidrag stöder kostnader för planeringsmöten, sammanföring av grundforskning samt klinisk forskning.

Research months for clinical projects

These grants enable cancer researchers with clinical service in medical, healthcare, social and behavioral science activities to set aside time for research. Funding includes a salary worth SEK 140,700 per month for a maximum of three years.

Closing date: 29 April 2021

Further information

Complementary clinical trials: expanding access to COVID-19 vaccines and rapid response to clinical development gaps - Coalition for Epidemic Preparedness Innovations (CEPI)

Supports clinical trials with the aim of rapidly expanding access to, and confidence in, COVID-19 vaccines. The total available budget is USD 140 million to support one or several clinical trials.

Closing date: 28 May 2021

Further information

Europeiska utlysningar

Gender in research fellowship — Netherlands Organisation for Health Research and Development (ZonMw) | Nederlandse Organisatie voor Wetenschappelijk Onderzoek, NL

This supports graduates and postdoctoral trainees in attending the gender and health course and participate in the gender in research workshop at the Erasmus summer programme, to be held in Rotterdam in August 2021.

Applicants must be registered in a doctoral programme or be within five years of completing their PhD. Applications are invited from all over the globe.

Up to 20 fellowships are available.

Closing date: 18 March 2021. This call is repeated once a year.

Further information

Public engagement grants -- Society for Endocrinology, GB

The Society for Endocrinology invites applications for its public engagement grants. These support the organisation and delivery of outreach activities, aimed at school children or the general public, that engage audiences with hormones and the impact of endocrinology. Activities may include the following:

•hands-on activities that can be used in classrooms;

•endocrine-themed science practicals;

•short, online videos or podcasts;

•online website material to reinforce concepts learnt in school.

Full and early-career members may apply. Grants are worth up to £1,000.

Closing date: 24 March 2021 (next deadline 22 September 2021)

Further information

Scientific training bursaries -- European League Against Rheumatism, EUR

These allow those working in the field of rheumatology in European countries to undertake clinical or laboratory work in another European country. Applicants must work predominantly in the field of rheumatology, be no more than 40 years of age and not already be abroad in training.

Bursaries are for a period of three to six months, at a rate of €1,000 per month plus €1,000 for travel expenses, up to a maximum total of €7,000.

Closing date: 31 March 2021 (next deadline 30 September 2021)

Further information

Call for research proposals -- ARSEP Foundation | Association pour l'Aide à la Recherche sur la Sclérose En Plaques, FR

This supports any basic and clinical research applications focused on multiple sclerosis. Two types of funding are available:

•research grants – worth up to €50,000 each, to be used for laboratory expenses, equipment and other project costs;

•fellowships – worth €57,000 for postdoctoral researchers based in France or internationally, provided that the researcher has performed their PhD research in France.

Research grant proposals must include at least one French team with a major role in the project. Fellowship applicants must be less than 40 years old on the deadline date, and they need not be French nationals. Funding is for one year.

Closing date: 31 March 2021. This call is repeated once a year.

Further information

Special topic networks -- European Society for Evolutionary Biology, EUR

This supports dynamic and flexible series of small meetings or other networking opportunities in focused and currently active research areas in evolutionary biology. Preference might be given to STNs that propose new connections between sub-disciplines or that focus on the resolution of current controversies.

Each network may receive up to €10,000 per year for up to six years.

Closing date: 31 March 2021

Further information

Research fellowship -- European Academy of Dermatology and Venereology, EUR

This enables young scientists to receive advanced training on basic or clinical research in dermatology or venereology in a high standard clinical or research centre in a country other than their own.

Dermatologists, venereologists, residents in dermatology-venereology and junior post-doctoral scientists with a special interest in dermatology or venereology may apply. Applicants must be of European nationality, be under 40 years of age and have previous published experience in the field of research they are planning to engage in or have a track record in skin research documented by their publication records.

Fellowships are worth up to €30,000 each over one year and cover travel, insurance costs and living expenses.

Closing date: 1 April 2021

Further information

Amerikanska utlysningar

Federal Funding agencies

Notice of Intent to Publish Research Opportunity Announcements (OTA-21-015) for the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Initiative, NIH

This Notice is to alert the community that NIH plans to publish Research Opportunity Announcements (ROAs) as part of the Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) initiative. The solicited research will improve understanding of and develop strategies to prevent and treat post-acute manifestations of SARS-CoV-2 infection across the lifespan. The initial ROAs are expected to be published by mid-February 2021. Projects will be funded utilizing NIH’s Other Transaction Authority (OTA), which offers flexibility and the ability to engage partners in collaborative innovation and problem solving. Initial awards are anticipated to be made in early March 2021.

Toward these ends, NIH plans initially to publish three ROAs to solicit applications for:

ROA #1

Clinical Research Studies targeting three domains: (a) Clinical Case-Based Recovery Meta-Cohort, (b) Autopsy Studies, and (c) EHR-/Health Systems-Based Analyses. Applications for this ROA may encompass one or more of these three domains.

ROA #2

Clinical Science Core,

ROA #3

Data Resource Core.

Funding Opportunity Announcement (FOA): OTA-21-015

Further information 

High-throughput Discovery and Validation of Novel Signal Transducers or Small Molecules that Modulate Opioid or other Substance Use Disorder Relevant Pathways (R01 - Clinical Trials Not Allowed), NIH

This FOA will support high-throughput screening approaches to identify novel receptors, signal transducers, or small molecules that modulate Substance Use Disorder (SUD)-relevant signal transduction pathways (dopamine, opioid, cannabinoid, nicotinic, or other appropriately justified pathway).

Closing date: September 15, 2021, by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): RFA-DA-22-006 (R01).

Further information  

Natural History of Disorders Screenable in the Newborn Period (R01 Clinical Trial Optional), NIH

This funding opportunity announcement (FOA) encourages applications that propose to develop studies that will lead to a broad understanding of the natural history of disorders that already do or could potentially benefit from early identification by newborn screening. A comprehensive understanding of the natural history of a disorder has been identified as a necessary element to facilitate appropriate interventions for infants identified by newborn screening. By defining the sequence and timing of the onset of symptoms and complications of a disorder, a valuable resource will be developed for the field. In addition, for some disorders, specific genotype-phenotype correlations may allow prediction of the clinical course, and for other disorders, identification of modifying genetic, epigenetic, or environmental factors will enhance an understanding of the clinical outcomes for an individual with such a condition. Comprehensive data on natural history will facilitate the field's ability to: 1) accurately diagnose the disorder; 2) understand the genetic and clinical heterogeneity and phenotypic expression of the disorder; 3) identify underlying mechanisms related to basic defects; 4) potentially prevent, manage, and treat symptoms and complications of the disorder; and 5) provide children and their families with needed support and predictive information about the disorder.

Closing date: standard due dates, by 5:00 PM local time of applicant organization until January 8, 2024.

Funding Opportunity Announcement (FOA): PAR-21-115 (R01).

Further information 

Basic Research to Inform Vaccine and Therapeutic Development for Non-Polio Human Enteroviruses (NPEV) (R01 Clinical Trial Not Allowed), NIH

The purpose of this funding opportunity announcement is to solicit applications to expand basic research on non-polio enteroviruses (NPEV) that will inform the development of pan-enterovirus vaccines and broad-spectrum antivirals against enteroviruses A, B, C, and D.

Closing date: July 13, 2021 by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): RFA-AI-21-006 (R01).

Further information 

Expert-Driven Small Projects to Strengthen Gabriella Miller Kids First Discovery (R03 Clinical Trial Not Allowed), NIH

The NIH Common Fund has established the Gabriella Miller Kids First Pediatric Research Program (Kids First) with the vision of alleviating suffering from childhood cancer and structural birth defects by fostering collaborative research to uncover the etiology of these diseases and supporting data sharing within the pediatric research community.

Kids First has established and continues to develop a Data Resource including a large collection of curated genomic and phenotypic data from childhood cancer and structural birth defects cohorts and a central portal where these data and analysis tools are accessible to the research community. This FOA is intended to engage experts in a variety of activities that will enhance the utility of childhood cancer and/or structural birth defects genomic datasets generated by the Kids First program and/or associated phenotypic datasets and resources. These activities should strengthen future analyses of Kids First datasets by the broader researcher community with the ultimate goal of improving diagnostic capabilities and therapies for children and their families affected by these conditions.

Closing date: June 18, 2021 by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement (FOA): RFA-RM-21-011 (R01).

Further information 

Breast Cancer Research Program (BCRP), Department of Defense (DoD), US

All FY21 BCRP applications must address at least one of the following overarching challenges unless adequate justification for exception is provided.* Simply identifying an overarching challenge is not sufficient. Applications must address the challenge in a way that can lead to or make a breakthrough and have a major impact.

  • Prevent breast cancer (primary prevention),
  • Identify determinants of breast cancer initiation, risk, or susceptibility
  • Distinguish deadly from non-deadly breast cancers,
  • Conquer the problems of overdiagnosis and overtreatment,
  • Identify what drives breast cancer growth; determine how to stop it,
  • Identify why some breast cancers become metastatic,
  • Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence,
  • Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival,
  • Eliminate the mortality associated with metastatic breast cancer,

*Alternatively, with adequate justification, applications may identify and address another overarching challenge related to the breast cancer landscape. Justification must be provided in the application.

Breakthrough Award Levels 1 and 2: Preproposal due March 11, 2021, Full proposal due on March 25, 2021

Funding level 1:

  • Maximum funding of $450,000 for direct costs (plus indirect costs). Maximum period of performance is years.
  • Innovative, high-risk/ high-reward research that is in the earliest stages of idea development or is an untested theory that addresses an important problem. To foster research that yields new avenues of investigation, preliminary data are not required. Proof of concept is the anticipated outcome.

Funding level 1 with Partnering PI Option:

  • Maximum funding of $750,000 for direct costs (plus indirect costs). Maximum period of performance is years.

Funding level 2:

  • Maximum funding of $1 million (M) for direct costs (plus indirect costs). Maximum period of performance is years.
  • Research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the breast cancer landscape.

 Funding Level 2 – Population Science and Prevention Studies:

  • Maximum funding of $1.5M for direct costs (plus indirect costs). The maximum period of performance is 4 years.
  • Research that is already supported by substantial preliminary or published data and strongly validates clinical translation in a well-defined context within the breast cancer landscape. With compelling justification, population science and prevention studies may request higher levels of funding and an additional year in the period of performance. Such studies may require additional resources due to the participation of human subjects and/or use of human biospecimens.

Funding level 2 with Partnering PI Option:

  • Maximum funding of $1.5 million (M) for direct costs (plus indirect costs). Maximum period of performance is years.

Funding Level 2 – Population Science and Prevention Studies – Partnering PI Option:

  • Maximum funding of $2M for direct costs (plus indirect costs). The maximum period of performance is 4 years.

Breakthrough Award Level 3: Preproposal due March 12, 2021, Full proposal due on March 23, 2021

Funding Level 3:

  • Maximum funding of $4M in direct costs (plus indirect costs). The maximum period of performance is 4 years.

Funding Level 3 with Partnering PI Option:

  • Maximum funding of $5M for direct costs (plus indirect costs). The maximum period of performance is 4 years.
  • Advanced translational studies with a high degree of project readiness. Where relevant, proof of availability of and access to necessary data, human samples, cohort(s), and/or critical reagents must be provided. If the proposed research would ultimately require U.S. Food and Drug Administration (FDA) involvement, applications must demonstrate availability of and access to clinical reagents (e.g., therapeutic molecules) and patient population(s). Applications must state a realistic timeline for near-term clinical investigation. Small-scale clinical trials (e.g., first in human; Phase I/Ib) may be appropriate.

Breakthrough Award Level 4: Preproposal due March 12, 2021, Full proposal due on March 23, 2021

Funding Level 4 and Funding Level 4 with Partnering PI Option:

  • Maximum funding of $10M for direct costs (plus indirect costs). The maximum period of performance is 4 years.
  • Large-scale projects that will transform and revolutionize the clinical management and/or prevention of breast cancer. Human clinical trials are required. PIs are expected to have experience in successfully leading large-scale projects and demonstrated ability (through personal experience or via a commitment from a collaborating clinical investigator) to implement a clinical project successfully. Where relevant, applications must demonstrate availability of and access to necessary data, human samples, cohort(s), and/or critical reagents.
  • Clinical trials are required.

Era of Hope Scholar Award: Preproposal due March 11, 2021, Full proposal due on March 25, 2021

  • Maximum funding of $3M for direct costs (plus indirect costs). The maximum period of performance is 4 years.
  • Supports individuals early in their careers who have demonstrated significant potential to effect meaningful change in breast cancer.
  • Individuals should be exceptionally talented scientists who have shown that they are the “best and brightest” in their field(s) through extraordinary creativity, vision, innovation, and productivity.
  • Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of their full-time effort during the award period to breast cancer research.

Innovator Award : Preproposal due March 12, 2021, Full proposal due on March 23, 2021

  • Maximum funding of $7M for direct costs (plus indirect costs). The maximum period of performance is 4 years.
  • Supports visionary individuals who have demonstrated exceptional creativity, innovative work, and paradigm-shifting leadership in any field including, but not limited to, breast cancer.
  • Provides these individuals with the opportunity and freedom to pursue novel, visionary, high-risk ideas that could accelerate progress toward ending breast cancer.
  • Experience in breast cancer research is not required; however, the application must focus on breast cancer, and the PI must maintain a 50% dedication of their full-time effort during the award period to breast cancer research.

Further information 

Ovarian Cancer Research Program (OCRP), Department of Defense (DoD), US

The mission of the OCRP is to support patient-centered research to prevent, detect, treat, and cure ovarian cancer to enhance the health and well-being of Service members, Veterans, their family members, and all women impacted by this disease.

Clinical Translational Research Award: Preproposal due April 1, 2021, Full proposal due on July 8, 2021

  • Maximum funding of $450,000 for direct costs (plus indirect costs). Maximum period of performance is 3 years.
  • Supports translational research addressing high-impact or unmet needs in ovarian cancer.
  • Supports correlative studies related to or associated with planned, ongoing, or completed clinical trials supported by other funding sources.
  • Emphasis on the utilization of precision medicine and computational approaches that identify individual tumor characteristics and predictive biomarkers across diverse groups to optimize patient care and outcomes.
  • Preliminary data are required.

Investigator-Initiated Research Award: Preproposal due April 1, 2021, Full proposal due on July 8, 2021

  • Maximum funding of $600,000 for direct costs (plus indirect costs). Maximum funding of $800,000 for direct costs (plus indirect costs) for Partnering PI Option. Maximum period of performance is 4 years.
  • Supports meritorious basic and clinically oriented research in ovarian cancer.
  • Impact is an important review criterion.
  • Preliminary data are required.

Ovarian Cancer Academy Award – Early-Career Investigator: Preproposal due April 1, 2021, Full proposal due on July 8, 2021

  • The OCA is a virtual career development and research training platform that consists of Early-Career Investigators (ECIs).
  • Maximum funding of $725,000 for direct costs (plus indirect costs). • Maximum period of performance is 4 years.
  • Supports the addition of new Early-Career Investigators to the unique, interactive virtual academy providing intensive mentoring, national networking, and a peer group for junior faculty.
  • Early-Career Investigators whose ability to commit to conducting ovarian cancer research is limited by lack of resources or other overwhelming obstacles are encouraged to apply.


Pilot Award: Preproposal due April 1, 2021, Full proposal due on July 8, 2021

  • Maximum funding of $250,000 for direct costs (plus indirect costs). Maximum period of performance is 2 years.
  • Supports innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward.
  • Innovation and Impact are important review criteria.
  • Goal is to develop preliminary data; thus, preliminary data are not required, but are allowed.


Proteogenomics Research Award: Preproposal due April 1, 2021, Full proposal due on July 8, 2021

  • Maximum funding of $250,000 for direct costs (plus indirect costs). Maximum period of performance is 2 years.
  • Supports the genomic and/or transcriptomic and/or proteomic analysis of currently available clinical specimens with a focus on answering biologic and pathophysiologic questions of clinical relevance in ovarian cancer.
  • Innovation and impact are important review criteria.
  • Analysis of clinical trial-derived specimens and/or large patient specimen cohorts is encouraged.
  • Preliminary data are not required but are allowed.

Further information 

Lung Cancer Research Program (LCRP), Department of Defense (DoD), US

To be considered for funding, applications for the FY21 LCRP Career Development Award must address at least one of the following Areas of Emphasis listed below:

  • Identify innovative strategies for prevention of the occurrence of lung cancer,
  • Identify innovative strategies for the screening and early detection of lung cancer,
  • Understand the molecular mechanisms of initiation and progression to lung cancer,
  • Understand contributors to lung cancer development other than tobacco,
  • Identify innovative strategies for the treatment of lung cancer,
  • Identify innovative strategies for the prevention of recurrence of or metastases from lung cancer,
  • Develop or optimize prognostic or predictive markers to assist with therapeutic decision-making,
  • Understand mechanisms of resistance to treatment (primary and secondary),
  • Identify innovative strategies for lung cancer care delivery (clinical management/ surveillance/symptom management),
  • Understand factors that contribute to the health disparities in lung cancer, such as biological contributors; environmental, social, and cultural factors; and access to health care.

Career Development Award: Preproposal due April 6, 2021, Full proposal due on April 20, 2021

  • Maximum funding of $250,000 in direct costs (plus indirect costs). Period of performance not to exceed 2 years.
  • Supports early-career, independent researchers to conduct research under the mentorship of an experienced lung cancer researcher.
  • Emphasis on research with high potential impact.
  • Clinical trials not allowed.
  • Career development plan is required with appropriate mentor guidance
  • Preliminary data not required.


Concept Award: Preproposal due April 6, 2021, Full proposal due on April 20, 2021

  • Maximum funding of $100,000 in direct costs (plus indirect costs). Period of performance not to exceed 1 year
  • Support untested, potentially groundbreaking concepts in lung cancer.
  • Emphasis on innovative concept or untested theory.

Further information 

Foundations

CRI Irvington Postdoctoral Fellowship Program, Cancer Research Institute, US

The CRI Irvington Postdoctoral Fellowship Program supports qualified young scientists at leading universities and research centers around the world who wish to receive training in fundamental immunology or cancer immunology. CRI seeks hypothesis-driven, mechanistic studies in both immunology and tumor immunology. The applicant and sponsor should make every effort to demonstrate the potential of the proposed studies to directly impact our understanding of the immune system’s role in cancer.

An Additional Opportunity

In collaboration with the Fibrolamellar Cancer Foundation, CRI has secured limited funding for additional postdoctoral fellowships for candidates whose projects are focused on understanding the immunological response to fibrolamellar carcinoma and accelerating the development of effective immunotherapy treatments for this rare, aggressive liver cancer that occurs predominantly in otherwise healthy adolescents and young adults.

Applicants should submit to the general CRI Irvington Postdoctoral Fellowship Program and any application in this area will be considered eligible for this special funding opportunity. This opportunity is in addition to our standard call for applications.

Budget: $175,500 over three years
Closing date: April 1 and October 1, 2021.

Further information